All News

Gregory Zagaja discusses the benefits of surgery for prostate cancer, as well as recent updates in the field.

Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.

A recent study revealed that people of color tend to have poorer prognoses than white people when diagnosed with melanoma.

The FDA granted ribociclib a breakthrough therapy designation for some patients with breast cancer.

Breast cancer and melanoma survivor shares time management tips to fellow survivors.

There must be a connection between chemo and AFIB.

Maintenance Revlimid was shown to improve overall survival in patients with multiple myeloma.

Pracinostat was granted a breakthrough therapy designation by the FDA for use in some patients with AML.

The addition of Onivyde to some chemotherapy regimens for pancreatic cancer improved survival and did not affect patients' quality of life.

Even with the many advances in cancer research, there are still limits to what medicine can achieve.

Handling two illnesses at once is not always easy.

Stanley Liauw discusses the current and future role of radiation therapy for patients with prostate cancer.

AI therapy can put breast cancer survivors at risk for bone fractures, making bone density monitoring important.

What happens when you meet an oncologist in training?

After cancer, calm and anxiety go from two separate states of mind to form a new way of thinking and perhaps even fighting the fears that come with being a cancer survivor.

Researchers are hoping to harness the leukemia-killing antibodies made by cured AML patients to treat others with the disease.

In treating low-risk breast cancer, adding novel agents isn't always necessary, Hope S. Rugo says.

One often hears cancer survivors proclaim with pride, honor and dignity, “I never asked why this happened to me.” Unintentionally, this sets the standard for those who follow, creating the unwritten rule that asking why is to admit weakness, to be unfit for battle.

Time is limited and the time for experiences with loved ones is today, writes breast cancer survivor Barbara Tako.

Every day seems to link another food or behavior to my cancer diagnosis. Those endless recommendations sometimes just minimize what I am going through. Am I wrong to say enough is enough?

The NCCN recently designated Optune, which has been shown to slow and reverse tumor growth, a category 2A recommendation for some patients with GBM.

CURE spoke with the founder of CORAL 65 on the unique issues older patients with cancer face.

Many people may not know about mastocytosis, but thanks to a new online initiative, patients and researchers are gaining a better understanding of the disorder.

The state of the world is a major buzzkill right now...

Tweet chats are no longer just a social way to share ideas. Now, cancer innovators have the opportunity to win grants that will help them develop their ideas on how to improve care.

With a number of FDA approvals, immunotherapy is becoming a key player in the treatment of lung cancer. CURE spoke with Mark W. Kris to see what's next.

Ruben Mesa discusses Jakafi's potential in treating myelofibrosis.

If you've relapsed after you thought you'd been cured, you know what a shock it is. Relapsing twice, after two transplants, turns out to have a surprisingly different effect on Kevin.

A male breast cancer survivor looks for answers from those who know best.

Two phase 3 trials led to Darzalex being granted a breakthrough therapy designation by the FDA.